Quarterly ResultMay 13, 2026, 06:13 AM
Takeda FY2026 Net Profit +77.7% to JPY 191.8B; Dividend JPY 200
AI Summary
Takeda Pharmaceutical reported its consolidated financial results for the fiscal year ended March 31, 2026, with net profit attributable to owners increasing by 77.7% to JPY 191.8 billion and basic EPS rising to JPY 121.75. However, revenue decreased by 1.7% to JPY 4,505.7 billion, primarily due to generic erosion of VYVANSE in Neuroscience, which saw a 26.8% decline. The company also declared an annual dividend of JPY 200.00 per share. For FY2027, Takeda forecasts a 3.0% increase in revenue to JPY 4,640.0 billion but anticipates a 13.4% decrease in net profit to JPY 166.0 billion.
Key Highlights
- FY2026 Net Profit attributable to owners: JPY 191.8 billion, up 77.7% AER.
- FY2026 Basic EPS: JPY 121.75, up from JPY 68.36 in FY2025.
- FY2026 Revenue: JPY 4,505.7 billion, down 1.7% AER.
- FY2026 Annual Dividend: JPY 200.00 per share, up from JPY 196.00.
- FY2027 Revenue Forecast: JPY 4,640.0 billion, up 3.0%.
- FY2027 Net Profit Forecast: JPY 166.0 billion, down 13.4%.
- Neuroscience revenue declined 26.8% AER to JPY 414.3 billion due to VYVANSE generic erosion.
- Issued JPY 184.0 billion in senior bonds and $2.4 billion in senior guaranteed notes.